• Logo
  • SBMUJournals

Inducible nitric oxide synthase as a potential blood-based biomarker in inflammatory bowel diseases

Saeed Baranipour, Azade Amini Kadijani, Durdi Qujeq, Shabnam Shahrokh, Mehrdad Haghazali, Alireza Mirzaei, Hamid Asadzadeh Aghdaei






Inflammatory bowel diseases, Inducible nitric oxide synthase, Biomarker


Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflam Res. 2014;7:113.

Ng SC. Emerging trends of inflammatory bowel disease in Asia. Gastroenterol Hepatol. 2016;12(3):193.

Viennois E, Zhao Y, Merlin D. Biomarkers of inflammatory bowel disease: from classical laboratory tools to personalized medicine. Inflam Bowel Dis. 2015;21(10):2467-74.

Hämäläinen M. Inducible nitric oxide synthase as a target of anti-inflammatory treatment modalities. Tampere University Press. 2008.

Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology. 2004;113(4):427-37.

Dijkstra G, Zandvoort AJ, Kobold AM, Jager-Krikken Ad, Heeringa P, Goor Hv, et al. Increased expression of inducible nitric oxide synthase in circulating monocytes from patients with active inflammatory bowel disease. Scan J Gastroenterol. 2002;37(5):546-54.

Mary J-Y, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30(7):983-9.

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Eng J Med. 1987;317(26):1625-9.

Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative CT method. Nat Protoc. 2008;3(6):1101.

Kim YG, Jang BI. The role of colonoscopy in inflammatory bowel disease. Clin Endosc. 2013;46(4):317.

Asadzadeh-Aghdaee H, Shahrokh S, Norouzinia M, Hosseini M, Keramatinia A, Jamalan M, et al. Introduction of inflammatory bowel disease biomarkers panel using protein-protein interaction (PPI) network analysis. Gastroenterol Hepatol Bed Bench. 2016;9(Suppl1):S8.

Burakoff R, Pabby V, Onyewadume L, Odze R, Adackapara C, Wang W, et al. Blood-based biomarkers used to predict disease activity in Crohn's disease and ulcerative colitis. Inflam Bowel Dis. 2015;21(5):1132-40.

Amini AK, Asadzadeh HA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Translat Gastroenterol. 2017;8(9):e117-e.

Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, et al. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018:2050640618774637.

Mirsattari D, Seyyedmajidi M, Zojaji H, Haghazali M, Orimi PG, Shoushtarizadeh T, et al. The relation between the level of interleukin-23 with duration and severity of ulcerative colitis. Gastroenterol Hepatol Bed Bench. 2012;5(1):49.

Boughton-Smith N, Evans S, Whittle B, Moncada S, Hawkey C, Cole A, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet. 1993;342(8867):338-e2.

Lundberg J, Hellström P, Lundberg J, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet. 1994;344(8938):1673-4.

Singer II, Kawka DW, Scott S, Weidner JR, Mumford RA, Riehl TE, et al. Expression of inducible nitric oxide synthase and nitrotyrosine in colonic epithelium in inflammatory bowel disease. Gastroenterology. 1996;111(4):871-85.

Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol. 2005;11(46):7227.

Baillie J, Soltis R. Systemic complications of inflammatory bowel disease. Geriatrics. 1985;40(2):53-6, 9-60.

DOI: https://doi.org/10.22037/ghfbb.v0i0.1527